Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial. (23rd December 2021)

• Record Type: Journal Article
• Authors: Cheng, Ying; Wang, Qiming; Li, Kai; Shi, Jianhua; Wu, Lin; Han, Baohui; Chen, Gongyan; He, Jianxing; Wang, Jie; Qin, Haifeng; Li, Xiaoling
• Is Part Of: Cancer medicine. Volume 11:Number 4(2022)
• Page Start: 1081
• Page End: 1087
• Publication Date: 2021-12-23
• Subjects: adverse events -- anlotinib -- liver metastasis -- small cell lung cancer -- survival; 616.994005
• DOI: 10.1002/cam4.4507
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Liver metastasis is common in advanced small cell lung cancer (SCLC). There is no evidence‐proven treatment beyond the second line in patients with SCLC and liver metastasis. This study aimed to investigate survival in patients with SCLC and liver metastasis treated with anlotinib compared with placebo. This study was a post hoc analysis of the phase II ALTER 1202 trial, including patients who had liver metastasis at baseline. The participants were randomized 2:1 to receive either 12 mg/day anlotinib (anlotinib group) or placebo (placebo group). Tumor response, progression‐free survival (PFS), and overall survival (OS) were compared. In the original trial, there were 39 participants with liver metastasis at baseline, including 27 and 12 in the anlotinib and placebo groups, respectively. The objective response rate was 3.7% and 0% in the anlotinib and placebo groups, respectively ( p = 0.9999). An elevated disease control rate was found in the anlotinib group (44.4%) compared with the placebo group (8.3%, p = 0.0173). The median PFS was 1.51 vs. 0.71 months in favor of anlotinib (hazard ratio [HR] = 0.365, 95% confidence interval [CI]: 0.17–0.78; p = 0.0064), with no marked difference in median OS (3.29 vs. 1.91 months; HR = 0.51, 95% CI: 0.22–1.16; p = 0.0996). The most common AEs in the anlotinib group were hypertension (40.7%), fatigue (29.6%), loss of appetite (22.2%), and weight loss (22.2%). There were no grade 5 AE. In conclusion, anlotinib increased PFS compared with placebo in patients with SCLC and liver metastasis. Abstract : This is a post‐hoc analysis of ALTER 1202 trial to investigate clinic benefit in patients with SCLC and liver metastases treated with anlotinib compared with placebo. Patients with liver metastases at baseline (27 in the anlotinib group and 12 in the placebo group) are included and significant improved median PFS is shown in anlotinib group.